Whitehawk Therapeutics WHWK 深 滬
交易中 09-25 12:05:41 美东时间
3.80
-0.060
-1.55%
華盛通- 最 高3.89
- 今 開3.85
- 成交量 3.20万股
- 最 低 3.765
- 昨 收 3.86
- 總市值 21.66万
- 52周最高 5.495
- 市盈率 靜 --
- 換手率 0.06%
- 52周最低 1.87
- 委 比 -9.29%
- 總股本 5.70万
- 歷史最高 65.25
- 量 比 0.15
- 振 幅 3.24%
- 歷史最低 1.21
- 每 手 1
- 風險率 0.91%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Whitehawk Therapeutics Adds Oncology Leader to Board
The latest update is out from Whitehawk Therapeutics ( ($WHWK) ). On September ...
09-11 05:29
Akari Therapeutics Says Strategic Research Collaboration With Whitehawk Therapeutics Expands Potential Application Of Akari’s PH1 Platform Into Dual-Payload ADCs
Expanded the Company's strategic position in novel ADC payloads through a research collaboration on dual ADC payloads with Whitehawk Therapeutics to evaluate Akari's proprietary PH1 spliceosome modulating payload platform in combination with Whitehawk's topoisomerase I payload platform. The collabor...
08-14 04:45
Whitehawk Therapeutics Q2 EPS $(0.20) Beats $(0.30) Estimate
Whitehawk Therapeutics (NASDAQ:WHWK) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.30) by 33.33 percent. This is a 73.68 percent increase over losses of $(0.76) per share from the same period last year.
08-06 20:46
Akari Therapeutics Announces Strategic Research Collaboration With Whitehawk To Conduct Preclinical Studies Evaluating PH1 Spliceosome-Modulating Payload Technology In Combination With TOP1i ADC Platform
Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today announced a strategic research collaboration with Whitehawk Therapeutics, a clinical-stage oncology therapeutics company applying adva...
07-21 19:15
Akari Therapeutics Enters Strategic Research Collaboration with Whitehawk Therapeutics
Akari Therapeutics and Whitehawk Therapeutics have entered into a strategic research collaboration to evaluate Akari's PH1 spliceosome-modulating payload technology in combination with Whitehawk's TOP1i ADC platform. The collaboration aims to explore dual payload compatibility and synergies, with Akari leading the research activities. Both companies will review interim data and assess potential broader development opportunities. This partnership ...
07-21 11:05
美股大行评级 | 花旗上调苹果、西部数据、希捷科技、超微电脑等目标价；高盛上调蔚来"买入"评级，目标价7美元
今日重点评级关注：HC Wainwright & Co.：维持艾吉纳斯"买入"评级，目标价从23美元升至30美元；富国银行：上调Q32 Bio评级至"超配"，目标价66美元
07-14 11:36
Leerink Partners Initiates Coverage On Whitehawk Therapeutics with Outperform Rating, Announces Price Target of $9
Leerink Partners analyst Jonathan Chang initiates coverage on Whitehawk Therapeutics (NASDAQ:WHWK) with a Outperform rating and announces Price Target of $9.
07-14 01:55
百奥赛图-B午后涨超12% 近日与Whitehawk达成全球战略合作
百奥赛图-B（02315）盘中涨超14%，截至发稿，股价上涨12.13%，现报52.70港元，成交额6343.89万港元。 近日，据百奥赛图官微消息，公司与...
07-10 11:50
Whitehawk Therapeutics Files Prospectus For Resale Of 22,321,887 Shares Of Common Stock
22,321,887 Shares of Common Stock This prospectus relates to the offer and resale from time to time of up to 22,321,887 shares (the "Shares") of common stock, par value $0.0001 per share, of Whitehawk Therapeutics,
05-30 04:22
Whitehawk Therapeutics Enters Into A New Option Agreement With Hangzhou DAC For Access To CPT113 For Use In Up To Five Additional ADC Programs; Phase 1 Dose-Escalation Trials Of HWK-007 And HWK-016 Are Currently Enrolling; HWK-007 Trials-In-Progress Poster To Be Presented At ASCO
Whitehawk Therapeutics, Inc. (NASDAQ:WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate
05-22 05:11
